Compare Enveric Biosciences Inc (ENVB) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Williams-Sonoma, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.80M), while Williams-Sonoma, Inc. trades at $242.52 (market cap $28.15B). The key difference: Williams-Sonoma, Inc. is far larger — about 4139.7× Enveric Biosciences Inc's market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Williams-Sonoma, Inc. for 59 Days on average.
| ENVB | WSM | |
|---|---|---|
Market Cap | $6.80M | $28.15B |
Volume | 64,867 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $251.81 |
52-Week Low | $1.27 | $168.64 |
Typical Hold Time | 14 Days | 59 Days |
Enterprise Value | -$1.49M | $28.65B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Williams-Sonoma (WSM) trades at $240.46, down 0.74% on the day, with a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.10 surpassing expectations. Revenue for 2025 was $7.71 billion, with a robust net income margin of 14.73% and high return on equity of 54.96%. Recent news highlights market share gains and AI integration driving growth.
The outlook remains positive with a consensus price target of $246.31, suggesting moderate upside. Key opportunities include sustained margin strength and digital initiatives, while risks involve housing market sensitivity and competitive pressures. Institutional sentiment is mixed with 32% buy ratings, but recent insider selling by the CFO warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
